Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Exscientia AI Limited
Conjupro Biotherapeutics, Inc.
Wake Forest University Health Sciences
Sotio Biotech Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
PMV Pharmaceuticals, Inc
BeOne Medicines
Monte Rosa Therapeutics, Inc
Neonc Technologies, Inc.
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Tasca Therapeutics
MacroGenics
MacroGenics
ImmunityBio, Inc.
DualityBio Inc.
Incyte Corporation
Janux Therapeutics
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
Incyte Corporation
National Institutes of Health Clinical Center (CC)
University of Virginia
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Marengo Therapeutics, Inc.
Shanghai Public Health Clinical Center
TransThera Sciences (Nanjing), Inc.
NRG Oncology
OncoC4, Inc.
Klus Pharma Inc.
University of California, San Francisco
Theratechnologies
SOLTI Breast Cancer Research Group
Stanford University
Seagen Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
23andMe, Inc.
AstraZeneca
Salubris Biotherapeutics Inc
Merck Sharp & Dohme LLC
Pfizer
Xencor, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
Evopoint Biosciences Inc.